CHRISTIE BALLANTYNE to Pyrroles
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Pyrroles.
Connection Strength
2.753
-
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul; 58(7):653-8.
Score: 0.206
-
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15; 93(12):1487-94.
Score: 0.205
-
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
Score: 0.197
-
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20; 107(19):2409-15.
Score: 0.190
-
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun; 240(2):490-6.
Score: 0.108
-
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2465-72.
Score: 0.104
-
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014 Nov; 37(11):3114-20.
Score: 0.104
-
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
Score: 0.101
-
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr; 15(4):380-8.
Score: 0.100
-
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26; 128(22):2395-403.
Score: 0.097
-
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J. 2013 Nov; 34(41):3182-90.
Score: 0.096
-
Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013 Jun; 34(24):1818-25.
Score: 0.095
-
Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
Score: 0.094
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
Score: 0.090
-
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 01; 365(22):2078-87.
Score: 0.086
-
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
Score: 0.083
-
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011 Jun; 27(6):1119-29.
Score: 0.082
-
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011 Feb; 25(1):59-67.
Score: 0.081
-
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
Score: 0.073
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15; 103(4):515-22.
Score: 0.070
-
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19; 52(8):626-32.
Score: 0.069
-
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15; 99(12):1706-1713.
Score: 0.063
-
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May; 151(5):975.e1-9.
Score: 0.058
-
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec; 26(24):2664-72.
Score: 0.056
-
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
Score: 0.048
-
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan 01; 91(1):33-41.
Score: 0.046
-
Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12; 158(18):1977-89.
Score: 0.035
-
Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996 Apr 01; 93(7):1334-8.
Score: 0.029
-
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
Score: 0.025
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.019
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
Score: 0.017
-
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging. 2004 Nov; 22(9):1249-58.
Score: 0.013
-
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001 Aug 15; 111(3):185-91.
Score: 0.011